share_log

DaVita Inc. (DVA) Q3 2024 Earnings Call Transcript Summary

DaVita Inc. (DVA) Q3 2024 Earnings Call Transcript Summary

DaVita Inc. (DVA) 2024年第三季度業績會致辭摘要
富途資訊 ·  10/30 09:54  · 電話會議

The following is a summary of the DaVita Inc. (DVA) Q3 2024 Earnings Call Transcript:

以下是德維特公司(DVA)2024年第三季度業績會實錄摘要:

Financial Performance:

金融業績:

  • Adjusted operating income for Q3 was $535 million.

  • Adjusted EPS for Q3 was $2.59.

  • The third quarter demonstrated minimal financial impact from hurricane-related disruptions, with an estimated Q4 impact of approximately $10 million to $20 million.

  • 第三季度調整後營業收入爲53500萬美元。

  • 第三季度調整後每股收益爲2.59美元。

  • 第三季度表現出的颶風相關干擾對財務影響較小,預計四季度影響約爲1,000萬至2,000萬美元。

Business Progress:

業務進展:

  • DaVita managed operational challenges and supply chain disruptions effectively during the hurricane season.

  • The company continues to focus on operational efficiencies and expansion in integrated kidney care and international markets.

  • Despite challenges, DaVita remains confident in continuing their growth trajectory into 2025.

  • 德維特在颶風季有效管理運營挑戰和供應鏈中斷。

  • 公司繼續專注於運營效率,並在綜合腎臟護理和國際市場擴展方面取得進展。

  • 儘管存在挑戰,德維特依然對自己能夠持續增長到2025年充滿信心。

Opportunities:

機會:

  • DaVita's ongoing focus on operational efficiencies and market expansion.

  • The anticipated regulatory transition regarding oral-only drugs could provide more comprehensive access to therapies, potentially boosting patient outcomes and operational efficiency.

  • 德維特持續關注運營效率和市場擴張。

  • 有關口服藥物的預期監管轉變可能提供更全面的療法,潛在地提升患者結果和運營效率。

Risks:

風險:

  • Supply chain disruptions from hurricane damages, particularly affecting the availability of peritoneal dialysis solutions and saline, resulting in a temporary suspension of new patient starts on PD and an estimated impact of $10 million to $20 million in Q4.

  • 受颶風破壞引起的供應鏈中斷,尤其影響腹膜透析液和生理鹽水的供應,導致腹透新患者暫時停止接納,預計在第四季度將造成1000萬 2000萬美元的影響。

Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.

提示:如需更全面的詳情,請參閱投資人關係網站。本文僅供投資者參考,不作任何指引或建議。

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論